COVID-19 PE: Nontraditional Risk Factors?

Risk factors for pulmonary embolism (PE) among patients with the new coronavirus are different from those traditionally observed.

Trombólisis local en tromboembolismo pulmonar

A French study recently published in Eur Heart J showed those new risk factors, and also that the risk of PE is reduced by the use of anticoagulant agents, just like in patients with conventional risk factors.

Initial reports had highlighted the increased incidence of PE among COVID-19 patients, but no consensus was reached regarding how and when anticoagulation should be indicated and at what dose.

This study suggests that anticoagulation therapy with a therapeutic dose administered before admission or anticoagulation therapy with a prophylactic dose during hospitalization could reduce the incidence of PE in accordance with the guidelines.

The study included 1240 patients hospitalized for COVID-19 among 24 French centers between February and April 2020. Overall, 103 (8.3%) subjects were diagnosed with PE by computed tomography pulmonary angiography.


Read also: Virtual ACC 2020 | CARAVAGGIO: Apixaban in Venous Thromboembolism Associated to Cancer.


Those with PE required intensive care (31.1% vs 13.5%) and mechanical ventilation (24.3% vs 7.3%) more frequently than patients without such complication (p < 0.001 for both).

No surprises here, so far. What is interesting is that the incidence of PE did not affect the risk of mortality (p = 0.038).

Patients who received anticoagulation before admission (regardless of the clinical indication or regime) or anticoagulation with a prophylactic dose introduced during hospitalization were at a lower risk for PE.


Read also: Catheter-directed thrombolysis for pulmonary embolism: a safe technique.


In a multivariate analysis, traditional risk factors such as age, history of cancer, history of thromboembolic disease, smoking, and obesity were not associated with PE incidence, nor were cardiovascular comorbidities like diabetes, hypertension, chronic heart failure, or coronary artery disease (p > 0.05 for all).

However, male sex, duration of hospital stay, and biomarker evidence of systemic inflammation actually were independent predictors of PE.

The risk for bleeding remains unclear, but this information seems to be enough to indicate antithrombotic prophylaxis for patients admitted with COVID-19, regardless of their risk factors.

Original title: Pulmonary Embolism in COVID-19 Patients: A French Multicentre Cohort Study.

Reference: Fauvel C. et al. Eur Heart J. 2020; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...